SB 160 Ohio Senate · 136th Legislature (2025-2026)

Regards prescription drugs and medication switching

SB 160 prohibits health insurance plans from making certain changes to drug coverage during a plan year, such as increasing patient costs, moving drugs to more restrictive tiers, or removing drugs from formularies (except for specific safety or manufacturer discontinuation reasons). It directly affects health insurance issuers and plan members by limiting how insurers can adjust coverage for prescription drugs. Key provisions include allowing generic substitution when available, preventing prior authorization for covered drugs, and exempting plans from restrictions if a drug’s cost rises more than 5% plus inflation. The bill aims to stabilize drug access for patients while permitting standard practices like formulary additions and generic substitutions.
Bill status passed 3 of 5 stages cleared
Introduction
Apr 2025
Committee Review
Apr 2025
Senate Passage
Jun 2026
House Passage
Governor
Introduced Apr 1, 2025 Last action Jun 16, 2026
Maddy AI version diff · 1 comparison

What changed between versions

As Introduced As Passed by the Senate · 4 edits · Jun 10, 2026
MODERATE
The bill was amended to clarify that health plans cannot move drugs to 'greater' cost-share tiers rather than just 'more restrictive' ones. It added a specific exception allowing plans to impose new prior authorization requirements for drugs that were not previously subject to such requirements within the same plan year. Additionally, the bill now explicitly permits pharmacists to substitute epinephrine autoinjectors, which was previously only implied.
Scope change
The bill's scope was expanded to explicitly include new prior authorization requirements as a prohibited action, whereas the original text only covered limiting or reducing existing coverage.
REQUIREMENT

Changed the prohibition on moving drugs from 'more restrictive tier' to 'greater cost-share tier' to ensure consistent terminology regarding cost-sharing levels.

Added a specific exception allowing health plans to subject a drug to a new prior authorization requirement during a plan year if the drug had not previously been subject to such a requirement.

Explicitly clarified that the bill does not prevent pharmacists from substituting one epinephrine autoinjector for another, removing ambiguity about this specific substitution.

TECHNICAL

Added a new section stating that the bill applies to health benefit plans delivered, issued, modified, or renewed on or after January 1, 2028.

Floor votes · Senate Jun 11, 2026

How they voted

330
Passed
Total votes 33
Jun 11, 2026
D Democratic9
9 Yea
100% Yea
R Republican24
24 Yea
100% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
6
Key actions
2
Committee
1
Jun 16, 2026
Introduced
Introduced
lower
Jun 11, 2026
Senate · Passed
Senate Vote: pass (33-0)
senate
Jun 10, 2026
Upper · Passed
Passed
upper
Apr 2, 2025
Committee
Referred to committee
upper
Apr 1, 2025
Introduced
Introduced
upper
2 primary · 0 co-sponsors

Sponsors